European equity markets posted solid gains on Tuesday, with the pan‑European STOXX 600 index up 0.8% to 638.41 points by 07:27 GMT, positioning the benchmark for a third consecutive session of advances.

Biotech boost lifts the market

Leading the rally, Danish biotech company Genmab surged 7.6% to become the top performer on the STOXX 600. The jump followed the release of data from a late‑stage study of a blood‑cancer therapy developed in partnership with U.S. drugmaker AbbVie. The trial showed a reduced risk of disease progression or death, providing a clear catalyst for the stock.

The broader healthcare sector also performed well, climbing 1.6% as investors weighed the positive clinical news alongside other sector fundamentals.

Bond market finds breathing room

Euro‑zone sovereign yields, which had surged to multi‑decade highs in the previous week, eased modestly on Tuesday. The retreat came after the market absorbed concerns over fiscal policy and inflation, offering a brief reprieve for fixed‑income investors.

Analysts noted that the easing came despite ongoing political uncertainty in the euro area, including the Spanish government’s decision to call a snap election, which has kept the euro near a 17‑month low.

Upcoming data could shape the next move

Market participants now look ahead to two key releases later in the day. Euro‑zone retail sales figures are expected to provide insight into consumer spending trends, while the United Kingdom’s S&P Global Purchasing Managers’ Index (PMI) survey will shed light on the health of Britain’s economy.

Both data points are likely to influence investor sentiment across equities and bonds, as they will help gauge the trajectory of demand and economic activity in the region.

French budget debate adds pressure

In France, the government is pushing an unpopular 2027 budget aimed at reducing the deficit. The fiscal plan has sparked a sell‑off in French bonds, contributing to the broader volatility in euro‑zone yields.

Meanwhile, Italian technology firm Technoprobe rose 2.3% after J.P. Morgan initiated coverage with an “overweight” rating, adding another positive note to the day’s market action.

Outlook

With biotech breakthroughs providing fresh optimism and bond yields showing signs of stabilization, European markets appear poised for continued strength, provided that upcoming economic data and political developments do not introduce new headwinds.

Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.